Furthermore, we tested how WBP5 expression could be modulated in different AML subtypes by analysing the mutational status of the two subgroups (WBP5high vs WBP5low); this approach demonstrated a correlation of high WBP5 expression with adverse cytogenetic findings such as NPM1c and FLT3-ITD, these being found in 43% vs 15% (p = 0.0000089) and in 40.2% vs 13.7% (p = 0.000013), respectively. Here, FLT3 is linked to acute myeloid leukemia.